HIV-related liver disease: infections versus drugs.
HIV-infected individuals have myriad causes of hepatotoxicity that range from mild hepatitis to significant liver failure with its associated morbidity and mortality, especially in the setting of chronic viral hepatitis (HCV and HBV). Immune restoration by HAART therapy can contribute liver-related toxicity in HIV-coinfected patients. Clinicians need to be aware of this problem and individualize management in this challenging clinical scenario. Avoidance of potentially hepatotoxic agents or close monitoring during treatment of HIV may prevent liver failure in patients who have HIV. Furthermore, vaccination against hepatitis A virus and HBV in nonimmune HIV individuals may prevent acquisition of hepatitis A virus and HBV infections in patients who have HIV. Finally, treatment of HIV, and, if appropriate, treatment of those who are coinfected with HCV and HBV with close monitoring, may improve the outcome of patients who have HIV and are at risk fo r significant hepatotoxicity during treatment from immune restoration or hypersensitivity reactions.
Sidiq
Homayon
H
St. Luke's Episcopal Hospital Center for Liver Disease, 6620 Main St. 15051, Houston, TX 77301, USA.
Ankoma-Sey
Victor
V
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D044966:Anti-Retroviral Agents / Q000009:adverse effects; D006509:Hepatitis B / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D015850:Interleukin-6 / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects
D044966:Anti-Retroviral Agents; D015850:Interleukin-6